Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -82.5%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $87836 | $6M | $235M | — | — | — |
| Enterprise Value | $-480212 | $5M | $229M | — | — | — |
| P/E Ratio → | -0.04 | — | — | — | — | — |
| P/S Ratio | 0.02 | 0.99 | 16.84 | — | — | — |
| P/B Ratio | 0.05 | 2.77 | 56.83 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.89 | 16.39 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | -11.5% | -11.5% | 18.2% | 13.9% | 27.7% | -10.4% |
| Operating Margin | -46.4% | -46.4% | -111.4% | -30.6% | 2.0% | -24.8% |
| Net Profit Margin | -44.3% | -44.3% | -111.7% | -29.9% | 1.3% | -24.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -82.5% | -82.5% | -806.7% | -57.7% | 4.7% | — |
| ROA | -44.6% | -44.6% | -273.9% | -42.2% | 2.2% | -66.3% |
| ROIC | — | — | — | — | 9.4% | — |
| ROCE | -76.9% | -76.9% | -542.5% | -65.1% | 4.3% | -228.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.10 | — | 0.01 | — |
| Debt / EBITDA | — | — | — | — | 0.26 | — |
| Net Debt / Equity | — | -0.28 | -1.52 | — | -0.87 | — |
| Net Debt / EBITDA | — | — | — | — | -31.81 | — |
| Debt / FCF | — | — | — | — | -10.34 | — |
| Interest Coverage | — | — | — | — | — | -32871.21 |
Net cash position: cash ($811920) exceeds total debt ($243872)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.06 | 1.06 | 2.31 | 1.09 | 5.97 | 0.94 |
| Quick Ratio | 0.99 | 0.99 | 2.26 | 1.03 | 5.93 | 0.80 |
| Cash Ratio | 0.61 | 0.61 | 2.14 | 0.89 | 5.80 | 0.25 |
| Asset Turnover | — | 1.65 | 1.76 | 2.29 | 0.90 | 2.76 |
| Inventory Turnover | 78.84 | 78.84 | 69.70 | 46.38 | 98.16 | 30.39 |
| Days Sales Outstanding | — | 23.55 | 4.74 | 12.04 | 10.30 | 47.32 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $29526 | $115868 | $141666 | $141666 | $141666 |
Imminent liquidity and solvency
According to recent financial statements, MNDR's gross margin deteriorated to -7.2% in 2025Q4, indicating that the direct costs of service delivery and pharmaceutical procurement consistently exceed the revenue generated, which suggests a fundamental lack of pricing power or operational scale within the current business model.
The persistent negative gross margin highlights a broken cost structure where the company is effectively subsidizing its own service delivery. Investors should monitor whether management can pivot toward higher-margin digital platform fees, as the current reliance on low-margin medical product sales appears to be a primary driver of the ongoing profitability crisis.
Based on reported figures, MNDR's cash conversion cycle reached -10 days in 2025Q4, which, while appearing efficient, likely reflects a forced acceleration of payables and a rapid liquidation of inventory rather than a sustainable improvement in operational efficiency or supplier leverage within the healthcare network.
The negative CCC is often a sign of financial strain in a contracting business, as the company may be delaying payments to providers to preserve cash. This strategy is likely unsustainable and may jeopardize the platform's ability to maintain its network of independent medical professionals over the long term.
As reported in the latest balance sheet, the company's current ratio of 1.06 in 2025Q4 leaves a razor-thin margin for error, especially given the rapid depletion of cash reserves from $9.8 million in 2023Q2 to just $811,920 in the most recent reporting period.
This liquidity position suggests that the company is highly vulnerable to any unexpected operational shocks or regulatory compliance costs. Without a significant infusion of capital or a rapid return to positive cash flow, the company may face severe challenges in meeting its short-term obligations.
Based on the company's reported figures, the ROIC of -111.8% in 2025Q4 reflects a profound inability to generate returns on invested capital, signaling that the current business model is actively destroying shareholder value rather than compounding it through its digital healthcare ecosystem.
The extreme negative ROIC is a clear indicator that the capital deployed into the platform is not yielding sufficient returns to cover the cost of operations. This trend warrants further investigation into whether the company's asset base, including significant goodwill, is appropriately valued given the ongoing revenue contraction.
Market participants often incorrectly apply traditional tech-based valuation multiples to MNDR, which obscures the reality that the company functions more like a distressed medical distributor with negative gross margins rather than a scalable, high-margin software platform capable of rapid, low-cost user acquisition.
Investors should focus on cash runway and unit economics rather than P/S or EV/EBITDA multiples, which are largely meaningless given the company's current financial distress. The reliance on these metrics may lead to an overestimation of the company's intrinsic value and a misunderstanding of its fundamental business risks.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MNDR stock.
Mobile-health Network Solutions Class A Ordinary Shares's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Mobile-health Network Solutions Class A Ordinary Shares's return on equity (ROE) is -82.5%. The historical average is -45.2%.
Based on historical data, Mobile-health Network Solutions Class A Ordinary Shares is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Mobile-health Network Solutions Class A Ordinary Shares has -11.5% gross margin and -46.4% operating margin.